DBVT - CIK 0001613780
DBV Technologies S.A. trades as DBVT and has a market capitalization of $1.11 B, making it the #2563 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $5.64M, up 35.8% from the prior year and net income of -$146.95M. This page tracks DBV Technologies S.A. through 563 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 6 fiscal years DBV Technologies S.A.'s revenue declined from $14.71M to $5.64M, a compound annual decline rate of 14.8%. Net profit margin compressed from -1169.5% to -2607.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-05-11 |
| Proxy statement | DEF 14A | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
The largest companies sharing DBV Technologies S.A.'s SEC industry classification (biological products, (no diagnostic substances)).
DBV Technologies S.A. (DBVT) has a market capitalization of $1.11 B as of 2026-05-29, ranking #2563 among US-listed companies.
DBV Technologies S.A. reported revenue of $5.64M for fiscal year 2025, an increase of 35.8% year over year.
In its latest fiscal year DBV Technologies S.A. reported a net loss of $146.95M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.